48,847
edits
Difference between revisions of "Malignant mesothelioma"
Jump to navigation
Jump to search
no edit summary
| Line 149: | Line 149: | ||
**[[TTF-1]]. | **[[TTF-1]]. | ||
**[[Ber-EP4]]. | **[[Ber-EP4]]. | ||
**100% of lung adenocarcinoma versus ~25% of mesotheliomas.<ref>{{cite journal |authors=Ordóñez NG |title=Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature |journal=Am J Clin Pathol |volume=109 |issue=1 |pages=85–9 |date=January 1998 |pmid= |doi=10.1093/ajcp/109.1.85 |url=}}</ref> | ***100% of lung adenocarcinoma versus ~25% of mesotheliomas.<ref>{{cite journal |authors=Ordóñez NG |title=Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature |journal=Am J Clin Pathol |volume=109 |issue=1 |pages=85–9 |date=January 1998 |pmid= |doi=10.1093/ajcp/109.1.85 |url=}}</ref> | ||
**MOC-31. | **MOC-31. | ||
**CD15. | **CD15. | ||